InflaRx (IFRX) stock

Anti-inflammatory medicines , market cap $200M

Anti-inflammatory medicines

Worth $200M

$1.21

-7.63%

As of Tuesday's close · Live for Pro members at the open

Why is IFRX down?

Down 7.6% today, more than its health care peers' 1.0%; no story names it yet.

Fell 31% since Nov 2

Down 31% from Nov 2 to Nov 10.

“InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan.”

Its release on Nov 6 said

Sources: Price history, Nov 10, 2026; Company release (8-K), Nov 6, 2026

−2Long-term trend below a falling 200-day average, down over two years

Tell me next time IFRX moves

Free account, no card. An optional alert when IFRX moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →1 more reason why IFRX fell 31% since Nov 2, from its filings, with the timeline and its peers, for Pro members.

Quality Score

-7

Poor

In its industry

#85of 90

Pharma

Checks firing

1of 14

Trending down

From 52-week high

-59.0%

under its best in a year

IFRX's Quality Score fell 2 points on Tue, Nov 10, to -7. It closed away from its high of the day (2 chart checks stopped).

Follow IFRX's news. Pro members can get an alert when InflaRx files news, and see its trials, share raises, and its CEO's filings.

Get an alert when IFRX files newsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEarly 2027“…a placebo-controlled randomized study in patients with renal involvement with site initiation in early 2027…”Trial start · SEC filing · Nov 3

Key facts on IFRX

Key facts on IFRX
Since its 2023 high	Down 79% sales EUR 63,089 → EUR 29,331 a year
Latest filing	6-K, Nov 6 Issued a release: "InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan"

1 more reason behind IFRX's -7, free with an account →3 more reasons behind IFRX's -7, for Pro members.

IFRX in the news

TodayNo story names it yet.

What's next

Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

IFRX catalysts

Coming up

After its last 4 reports it closed -0.4% on average, higher 2 of 4 times.

4 more coming up, with sizes and sources, for Pro members.

What's next for IFRX, and how long its cash lasts

Next step the company has named

Early 2027“…program expected to include a placebo-controlled randomized study in patients with renal involvement with site initiation in early 2027, as well as an open-label “all-comers” study to”Trial start · SEC filing · Nov 3

What it means: when a trial begins, or reaches the stage the company named.

For Pro members: 5 more milestones and 46 filings.

Cash runway Dec 31, 2025 balance sheet

EUR 16M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “through 2029” (8-K, Nov 3). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (F-3, filed Aug 6, 2026)
At-the-market share sales program (424B5, filed Aug 14, 2026)

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when Niels Riedemann buys or sells

For Pro members: every trade, and Niels Riedemann’s 1 filing and quote.

Get an alert when IFRX files newsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How IFRX ranks in Pharma

IFRX is #85 of 90 by Quality Score.

How IFRX ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	10/14	23
2	LLYEli Lilly	8/14	21
3	PFEPfizer	6/14	17
	HROWHarrow		Open for its score
	IDXXIdexx Laboratories		Open for its score
	INSMInsmed		Open for its score
	INVAInnoviva		Open for its score
85	IFRXInflaRx	1/14	-7

When does IFRX report earnings, and what happens after?

Expected to report Thu Mar 18, before the open (in 128 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 4

+3.4%+6.0%-2.8%-8.2%

Mar 19May 7Aug 6Nov 3

Reported	When	Gap	Reaction	5 days
Nov 3, 2026Before open	Before open	-5.4%	-8.2%	-25.8%
Aug 6, 2026Before open	Before open	0.0%	-2.8%	+13.6%
May 7, 2026Before open	Before open	-4.4%	+6.0%	+0.8%
Mar 19, 2026Before open	Before open	-1.1%	+3.4%	+6.8%

IFRX closed higher after 2 of its last 4 reports.

IFRX sales and profit by year

Sales and profit by year

Sales grew in one of the last two years, to €29K in 2025. It lost money in each of the three years.

IFRX has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on IFRX, and all 14 on every stock.Get in free →

IFRX RSI today: 30.0, below its 50-day and 200-day averages

Not scored

RSI 30.0, MACD below signal, below both averages. Not scored.13 readings

The deep dive on IFRX

What it does and how it makes money3 findingsA loss before tax of €45.6M in fiscal 2025, on €29K of sales.Annual report, filed Mar 20, 2026"Pursuant to the agreement, we are entitled to receive mid-single-digit percentage royalties on net sales of BDB’s products containing BDB-001 or BDB-002." (20-F for fiscal 2025)SEC filing · Mar 20, 2026
Where it stands1 findingFor Pro members1 finding on where IFRX stands: its cash, debt, and share count, for Pro members
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades IFRX, for Pro members

3 more findings on IFRX, each with its source, for Pro members.

IFRX share count over time

Shares of IFRX outstanding, as filed
Shares outstanding	As of
72.3M	Dec 31, 2025
59.4M	Dec 31, 2024
58.9M	Dec 31, 2023
44.7M	Dec 31, 2022

Offerings, shelves, and splits of IFRX, from its filings
From its filings	Filed
Set up an at-the-market program for up to $65M of shares, about 33% of its market value	Aug 14, 2026
Registered shares for a later sale (F-3)	Aug 6, 2026
Raised $150M in a sale of shares, about 75% of its market value	May 7, 2026
Raised $16.5M in a sale of shares, about 8% of its market value	Feb 18, 2025

About InflaRx

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

65 employeesinflarx.de

What InflaRx says it competes with

“The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”

From its annual report, SEC filing · Mar 20, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on IFRX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn IFRX's score around: 7 things
9 more filings explained, a plain line each
4 more things pulling IFRX's score down

See IFRX's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: IFRX's Quality Score is -7 (Poor), #85 of 90 in Pharma.

What does IFRX's Quality Score say?

IFRX scores -7 today, which Breakaway calls Poor. It is #85 of 90 in Pharma by Quality Score, with 1 of 14 chart checks firing. Down 31% from Nov 2 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is IFRX's Quality Score?

IFRX scores -7 today, which Breakaway calls Poor (below zero). That is #85 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IFRX's -7.

When does IFRX report earnings?

Expected to report Thu Mar 18, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. IFRX closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.